Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Novavax Stock: Buy, Sell, or Hold in 2023?
11:00am, Thursday, 24'th Nov 2022 The Motley Fool
The shares are heading for almost a 90% loss this year.
Novavax (NVAX) Cancels COVID Jab Supply Deal With GAVI
05:35pm, Wednesday, 23'rd Nov 2022 Zacks Investment Research
Novavax (NVAX) claims that GAVI's failure to procure its COVID vaccine doses is a reason to terminate the supply agreement. GAVI denies the company's claims and a legal battle is likely to follow.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
02:00pm, Wednesday, 23'rd Nov 2022 Zacks Investment Research
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
10:32am, Wednesday, 23'rd Nov 2022
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
China's three-week COVID case tally tops 253,000 and daily average is rising, government says
03:10pm, Tuesday, 22'nd Nov 2022 MarketWatch
More than 253,000 coronavirus cases have been found in China in the past three weeks and the daily average is rising
Japan approves COVID antiviral pill as Pfizer, Merck alternative
07:24am, Tuesday, 22'nd Nov 2022
TOKYO—Japan approved an antiviral pill from Shionogi & Co. to treat Covid-19 after the company provided new data to show the drug's efficacy.
Pfizer (PFE), BioNTech Provide New Data on BA.4/BA.5 Boosters
07:32am, Monday, 21'st Nov 2022
Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccines show improved immune response against newer Omicron sublineages.
2 Reasons to Buy Pfizer and 1 Reason to Sell
09:37am, Sunday, 20'th Nov 2022
The pharmaceutical company is looking for a future beyond COVID-19 therapies.
Cramer: Positive Pfizer vaccine trial takes 'impending doom' off the table
10:19am, Saturday, 19'th Nov 2022
CNBC's "Squawk on the Street" team discusses the news that Pfizer's Covid vaccine appears to be 100% effective in 12- to 15-year-olds.
Pfizer now administering Covid vaccine does to children under age 12 in trial
09:59am, Saturday, 19'th Nov 2022
CNBC's Meg Tirrell reports on latest news from Pfizer, which has started to give the Covid vaccine to children under the age of 12 as part of a new trial.
White House advisor Dr. Fauci recounts the first time he heard results on Pfizer's Covid vaccine
09:33am, Saturday, 19'th Nov 2022
CNBC's "Squawk on the Street" crew reflect on the evolution of the coronavirus vaccine rollout and how the markets have reacted over the year to news from the pharmaceutical industry.
3 Unstoppable Growth Stocks to Buy and Hold
09:15am, Saturday, 19'th Nov 2022
These businesses are built for the long run.
FDA allows Pfizer to store Covid vaccine at normal freezer temperatures for 2 weeks
08:57am, Saturday, 19'th Nov 2022
CNBC's Meg Tirrell reports the FDA has allowed Pfizer to store its Covid vaccines at normal freezer temperatures for two weeks. This will allow for easier storage for Pfizer vaccines, which previously
Pfizer CEO Albert Bourla on Covid vaccine manufacturing outlook
07:13am, Saturday, 19'th Nov 2022
Pfizer CEO Albert Bourla told CNBC's "Squawk Box" Tuesday that the company plans to increase coronavirus vaccine production this year, with a goal of manufacturing up to two billion doses.
Biden gets second dose of Pfizer vaccine
07:02am, Saturday, 19'th Nov 2022
President-elect Joe Biden got his second shot of the Pfizer Covid-19 vaccine today.
